Skip to main content

Peer Review reports

From: EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Original Submission
24 Apr 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
14 Jun 2022 Reviewed Reviewer Report
6 Aug 2022 Reviewed Reviewer Report
1 Sep 2022 Author responded Author comments - Haiyong Wang
Resubmission - Version 4
1 Sep 2022 Submitted Manuscript version 4
6 Sep 2022 Author responded Author comments - Haiyong Wang
Resubmission - Version 5
6 Sep 2022 Submitted Manuscript version 5
Publishing
13 Sep 2022 Editorially accepted
19 Sep 2022 Article published 10.1186/s12890-022-02161-1

You can find further information about peer review here.

Back to article page